Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance

Type 2 diabetes mellitus (T2DM) increases morbimortality in humans via enhanced susceptibility to cardiovascular disease (CVD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are drugs designed for T2DM treatment to diminish hyperglycaemia by reducing up to 90% of renal tube glucose reabsorptio...

Full description

Bibliographic Details
Main Authors: Alida Taberner-Cortés, Ángela Vinué, Andrea Herrero-Cervera, María Aguilar-Ballester, José Tomás Real, Deborah Jane Burks, Sergio Martínez-Hervás, Herminia González-Navarro
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:International Journal of Molecular Sciences
Subjects:
type 2 diabetes
SGLT2i
glucose metabolism
insulin resistance
atherosclerosis
Online Access:https://www.mdpi.com/1422-0067/21/23/9216

Internet

https://www.mdpi.com/1422-0067/21/23/9216

Similar Items